Atossa Therapeutics (ATOS +23.8%) announces positive results from in vitro testing of AT-301, its proprietary COVID-19 nasal spray drug candidate.
Preliminary data showed that AT-301 inhibited SARS-CoV-2 infectivity of VERO cells in lab culture, the standard model for initial screening of COVID-19 drug candidates.
The company says AT-301 contains ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation.
A Phase 1 clinical study is next up.
Atossa has filed provisional patent applications with the USPTO directed to the formulation, manufacturing, and methods of use of AT-301.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.